Pneomovax 23, Pnu-Immune 23 (PPSV23)

Question 0

INDICATION

Answer 0

(1) all adults age 65 years and older

(2) age 2-64 w/ any of the following conditions:
(a) cigarette smokers age 19 and older
(b) chronic CV disease
(c) chronic pulmonary disease (COPD, emphysema, asthma for 19 and older)
(d) diabetes
(e) alcoholism
(f) chronic liver disease, cirrhosis
(g) recipient or candidate for cochlear implant
(h) CSF leak
(i) functional or anatomic asplenia (sickle cell disease, splenectomy)
(j) immunocompromised conditions
(k) organ transplantation
(l) chronic renal failure or nephrotic syndrome

Question 1

TYPE / ROUTE

Answer 1

Inactive, IM or SC

Question 2

DOSE

Answer 2

0.5 mL

Question 3

OF DOSES

Answer 3

1

Question 4

FREQUENCY

Answer 4

(1) 1 dose at least 8 weeks after final dose of PCV13 to high-risk children age 2 years and older
(2) 1 dose at age 65 years and older if unvaccinated or if previous history unknown
(3) 1 time revaccination to people:

(a) 65 years and older if 1st dose was given prior to age 65 and if 5 years have elapsed since 1st dose
(b) 19-64 years who are at highest risk of fatal pneumococcal infection or rapid antibody loss and if 5 years have elapsed since 1st dose

Question 5

CONTRAINDICATIONS

Answer 5

severe allergic rxn after a previous dose or to a vaccine component

Question 6

PRECAUTIONS

Answer 6

(1) moderate or severe acute illness w/ or w/out fever
(2) use caution and appropriate care for individuals w/ severely compromised CV and/or pulmonary function in whom a system rxn would pose a significant risk

Question 7

ADVERSE REACTIONS

Answer 7

injection site pain/ soreness/ tenderness/ swelling/ induration/ erythema, fatigue, myalgia, headache